# Novel phenolic constituents of *Pulmonaria officinalis* L. LC-MS/MS comparison of spring and autumn metabolite profiles

## Justyna Krzyżanowska-Kowalczyk<sup>1\*</sup>, Łukasz Pecio<sup>1</sup>, Jarosław Mołdoch<sup>1</sup>, Agnieszka Ludwiczuk<sup>2</sup>, Mariusz Kowalczyk<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Crop Quality, Institute of Soil Science and Plant Cultivation - State Research Institute, Czartoryskich 8, 24-100 Puławy, Poland; jkrzyzanowska@iung.pulawy.pl (J.K.K.); lpecio@iung.pulawy.pl (Ł.P); jmoldoch@iung.pulawy.pl (J.M.); mkowalczyk@iung.pulawy.pl (M.K.)

<sup>2</sup>Department of Pharmacognosy with Medicinal Plant Unit, Medical University of Lublin, Chodzki Str.1, 20-093 Lublin, Poland; aludwiczuk@pharmacognosy.org(A.L.)

\*Correspondence:jkrzyzanowska@iung.pulawy.pl; Tel.: +48-81-4786-881

## Spis treści

Figure 1S.	<sup>1</sup> H (500 MHz) and <sup>13</sup> C (125 MHz) NMR data of compound 1 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum MeCN/H <sub>2</sub> O	in 6
Figure 2S.	$^{1}\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 2 in CD3OD, 25°C; on-line PDA UV spectrum MeCN/H2O	in 6
Figure 3S.	<sup>1</sup> H (500 MHz) and <sup>13</sup> C (125 MHz) NMR data of compound 3 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum MeCN/H <sub>2</sub> O, ECD spectrum in MeOH	in 7
Figure 4S.	<sup>1</sup> H NMR spectrum of compound 3	7
Figure 5S.	<sup>13</sup> C UDEFT NMR spectrum of compound 3	8
Figure 6S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 3	8
Figure 7S.	<sup>1</sup> H- <sup>1</sup> H TROESY (250 ms) NMR spectrum of compound 3	9
Figure 8S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 3	9
Figure 9S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 3	10
Figure 10S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 3	10
Figure 11S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 4 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum MeCN/H <sub>2</sub> O, ECD spectrum in MeOH	in 11
Figure 12S.	$^{1}$ H (500 MHz) $^{13}$ C (125 MHz) and $^{15}$ N (50 MHz) NMR data of compound 5 in CD <sub>3</sub> OD, 25°C	11
Figure 13S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 7 in CD $_{3}$ OD, 25°C	12
Figure 14S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 10 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	n 12
Figure 15S.	<sup>1</sup> H NMR spectrum of compound 10	13
Figure 16S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 10	13
Figure 17S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 10	14
Figure 18S.	<sup>1</sup> H- <sup>1</sup> H TROESY (250 ms) NMR spectrum of compound 10	14
Figure 19S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 10	15
Figure 20S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 10	15
Figure 21S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 10	16
Figure 22S.	<sup>1</sup> H (500 MHz) and <sup>13</sup> C (125 MHz) NMR data of compound 11 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrur in MeOH	n .16
Figure 23S.	<sup>1</sup> H (500 MHz) and <sup>13</sup> C (125 MHz) NMR data of compound 12 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrur in MeOH	n .17
Figure 24S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 14 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeOH	n .17
Figure 25S.	<sup>1</sup> H NMR spectrum of compound 14	18
Figure 26S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 14	18
Figure 27S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 14	19
Figure 28S.	<sup>1</sup> H- <sup>1</sup> H NOESY (400 ms) NMR spectrum of compound 14	19
Figure 29S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 14	20
Figure 30S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 14	20
Figure 31S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 14	21
Figure 32S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 15 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	n 21

Figure 33S.	$^{1}\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 18 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeOH	n 22
Figure 34S.	<sup>1</sup> H NMR spectrum of compound 18	22
Figure 35S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 18	23
Figure 36S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 18	23
Figure 37S.	<sup>1</sup> H- <sup>1</sup> H TROESY (250 ms) NMR spectrum of compound 18	24
Figure 38S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 18	24
Figure 39S.	<sup>1</sup> H- <sup>13</sup> C 1,1-ADEQUATE NMR spectrum of compound 18	25
Figure 40S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 18	25
Figure 41S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 19 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 26
Figure 42S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 21 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 26
Figure 43S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 22 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 27
Figure 44S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 23 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 27
Figure 45S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 24 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 28
Figure 46S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 25 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 28
Figure 47S.	$^{1}\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 26 in DMSO-d <sub>6</sub> , 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	29
Figure 48S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 27 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeOH	า 29
Figure 49S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 28 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 30
Figure 50S. in MeCN/H <sub>2</sub> O;	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 29 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum ECD spectrum in MeOH	n 30
Figure 51S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 30 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 31
Figure 52S.	<sup>1</sup> H NMR spectrum of compound 30	31
Figure 53S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 30	32
Figure 54S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 30	32
Figure 55S.	<sup>1</sup> H- <sup>1</sup> H TROESY (250 ms) NMR spectrum of compound 30	33
Figure 56S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 30	33
Figure 57S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 30	34
Figure 58S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 30	34
Figure 59S.	<sup>1</sup> H (500 MHz) and <sup>13</sup> C (125 MHz) NMR data of compound 31 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 35
Figure 60S.	$^{1}\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 32 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	า 35
Figure 61S.	<sup>1</sup> H NMR spectrum of compound 32	36
Figure 62S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 32	36

Figure 63S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 32	37
Figure 64S.	<sup>1</sup> H- <sup>1</sup> H TROESY (250 ms) NMR spectrum of compound 32	37
Figure 65S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 32	38
Figure 66S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 32	38
Figure 67S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 32	39
Figure 68S.	$^{1}\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 33 in CD3OD, 25°C; on-line PDA UV spectrum in MeCN/H2O	n .39
Figure 69S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 34 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeOH	n .40
Figure 70S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 35 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeOH	n .40
Figure 71S.	<sup>1</sup> H NMR spectrum of compound 35	41
Figure 72S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 35	41
Figure 73S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 35	42
Figure 74S.	<sup>1</sup> H- <sup>1</sup> H TROESY (250 ms) NMR spectrum of compound 35	42
Figure 75S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 35	43
Figure 76S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 35	43
Figure 77S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 35	44
Figure 78S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 36 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeOH	n .44
Figure 79S.	$^{1}\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 37 in CD3OD, 25°C; on-line PDA UV spectrum in MeCN/H2O	n .45
Figure 80S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 38 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum in MeCN/H <sub>2</sub> O	n .45
Figure 81S.	<sup>1</sup> H NMR spectrum of compound 38	46
Figure 82S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 38	46
Figure 83S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 38	47
Figure 84S.	<sup>1</sup> H- <sup>1</sup> H NOESY (300 ms) NMR spectrum of compound 38	47
Figure 85S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 38	48
Figure 86S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 38	48
Figure 87S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 38	49
Figure 88S.	$^{1}$ H (500 MHz) and $^{13}$ C (125 MHz) NMR data of compound 39 in CD $_{3}$ OD, 25°C	49
Figure 89S.	<sup>1</sup> H NMR spectrum of compound 39	50
Figure 90S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 39	50
Figure 91S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 39	51
Figure 92S.	<sup>1</sup> H- <sup>1</sup> H NOESY (300 ms) NMR spectrum of compound 39	51
Figure 93S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 39	52
Figure 94S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 39	52
Figure 95S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 39	53
Figure 96S.	<sup>1</sup> H (500 MHz) and <sup>13</sup> C (125 MHz) NMR data of compound 40 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrur in MeCN/H <sub>2</sub> O; ECD spectrum in MeOH	n .53

Figure 97S.	<sup>1</sup> H (500 MHz) and <sup>13</sup> C (125 MHz) NMR data of compound 41 in CD <sub>3</sub> OD, 25°C; on-line PDA UV spectrum			
	in MeCN/H <sub>2</sub> O; ECD spectrum in MeOH54			
Figure 98S.	<sup>1</sup> H NMR spectrum of compound 4154			
Figure 99S.	<sup>13</sup> C DEPTQ NMR spectrum of compound 4155			
Figure 100S.	<sup>1</sup> H- <sup>1</sup> H COSY NMR spectrum of compound 4155			
Figure 101S.	<sup>1</sup> H- <sup>1</sup> H TROESY (250 ms) NMR spectrum of compound 4156			
Figure 102S.	<sup>1</sup> H- <sup>13</sup> C HSQC NMR spectrum of compound 4156			
Figure 103S.	<sup>1</sup> H- <sup>13</sup> C H2BC NMR spectrum of compound 4157			
Figure 104S.	<sup>1</sup> H- <sup>13</sup> C HMBC (8 Hz) NMR spectrum of compound 4157			
Figure 105S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 43 in CD_3OD, 25°C; on-line PDA UV spectrum in MeCN/H2O			
Figure 106S.	$^1\text{H}$ (500 MHz) and $^{13}\text{C}$ (125 MHz) NMR data of compound 44 in CD_3OD, 25°C; on-line PDA UV spectrum in MeCN/H2O58			
Table S1				
Figure 107S.	Frequency distribution of the relative standard deviation for the peak intensities and peak numbers in QC samples			



(3,4-dihydroxyphenyl)lactic acid

Figure 1S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 1 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



1. Seigler, D.S., Pauli, G.F., Fröhlich, R., Wegelius, E., Nahrstedt, A., Glander, K.E., Ebinger, J.E., 2005. Cyanogenic glycosides and menisdaurin from Guazuma ulmifolia, Ostrya virginiana, Tiquilia plicata, and Tiquilia canescens. Phytochemistry 66, 1567–1580. doi:10.1016/j.phytochem.2005.02.021

Figure 2S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 2 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 3S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 3 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O, ECD spectrum in MeOH



Figure 4S. <sup>1</sup>H NMR spectrum of compound 3



Figure 5S. <sup>13</sup>C UDEFT NMR spectrum of compound 3



Figure 6S. 1H-1H COSY NMR spectrum of compound 3



Figure 7S. 1H-1H TROESY (250 ms) NMR spectrum of compound 3



Figure 8S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 3



Figure 9S. <sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 3



Figure 10S. <sup>1</sup>H-<sup>13</sup>C HMBC (8 Hz) NMR spectrum of compound 3



1. Kuczkowiak, U., Petereit, F., Nahrstedt, A., 2014. Hydroxycinnamic Acid Derivatives Obtained from a Commercial Crataegus Extract and from Authentic Crataegus spp. Sci. Pharm. 82, 835–846. doi:10.3797/scipharm.1404-02 2. Parveen, I., Winters, A., Threadgill, M.D., Hauck, B., Morris, P., 2008. Extraction, structural characterisation and evaluation of hydroxycinnamate esters of orchard grass (Dactylis glomerata) as substrates for polyphenol oxidase Phytochemistry 69, 2799–2806. doi:10.1016/j.phytochem.2008.08.019





#### Lycoperodine-1



1. Murai, F., Tagawa, M., 1989. Relationship between ionone glycosides and terpenoids in Actinidia polygama, in: Abstract Papers of the 33rd Symposium on the Chemistry of Terpenes, Essential Oils, and Aromatics (TEAC), Sendai. pp. 68–70. 2. Otsuka, H., Hirata, E., Shinzato, T., Takeda, Y., 2003. Stereochemistry of megastigmane glucosides from Glochidion zeylanicum and Alangium premnifolium. Phytochemistry 62, 763–768. doi:10.1016/S0031-9422(02)00614-3



Figure 13S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 7 in CD<sub>3</sub>OD, 25°C

**3'-O-(E)-Feruoyl-**α-sorbopyranosyl-(2' $\rightarrow$ 1)-α-glucopyranoside

Figure 14S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 10 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O

<sup>1</sup>H NS16 CD30D 25° C -- NS=16



Figure 15S. <sup>1</sup>H NMR spectrum of compound 10



Figure 16S. <sup>13</sup>C DEPTQ NMR spectrum of compound 10



Figure 17S. <sup>1</sup>H-<sup>1</sup>H COSY NMR spectrum of compound 10



Figure 18S. <sup>1</sup>H-<sup>1</sup>H TROESY (250 ms) NMR spectrum of compound 10



Figure 19S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 10



Figure 20S. <sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 10







1. Hahn, R., Nahrstedt, A., 1993. Hydroxycinnamic acid derivatives, caffeoylmalic and new caffeoylaldonic acid esters, from Chelidonium majus. Planta Med. 59, 71–75. doi:10.1055/s-2006-959608 \* http://www.drugfuture.com/chemdata/glyceric-acid.html

**Figure 22S.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 11 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH



Hahn, R., Nahrstedt, A., 1993. Hydroxycinnamic acid derivatives, caffeoylmalic and new caffeoylaldonic acid esters, from Chelidonium majus. Planta Med. 59, 71–75. doi:10.1055/s-2006-959608





Figure 24S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 14 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH

*€*H NS16 CD30D+TFA 25*€*C - 5x diluted - NS=16







Figure 26S. <sup>13</sup>C DEPTQ NMR spectrum of compound 14



Figure 27S. <sup>1</sup>H-<sup>1</sup>H COSY NMR spectrum of compound 14



2D NOESY 400ms (solv suppr) - NS=6

Figure 28S. <sup>1</sup>H-<sup>1</sup>H NOESY (400 ms) NMR spectrum of compound 14



Figure 29S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 14



Figure 30S. <sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 14







Figure 32S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 15 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



1. Basli, A., Delaunay, J.-C., Pedrol, E., Bernillon, S., Madani, K., Monti, J.-P., Mérillon, J.M., Chibane, M., Richard, T., 2014. New Cyclolignans from Origanum glandulosum Active Against 8-amyloid Aggregation. Rec. Nat. Prod. 8, 208–216. 2. Assoumatine, T., Datta, P.K., Hooper, T.S., Yvon, B.L., Charlton, J.L., 2004. A Short Asymmetric Synthesis of (+)-Lyoniresinol Dimethyl Ether. J. Org. Chem. 69, 4140–4144. doi:10.1021/j00497454

**Figure 33S.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 18 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH



Figure 34S. <sup>1</sup>H NMR spectrum of compound 18







Figure 36S. 1H-1H COSY NMR spectrum of compound 18



Figure 37S. <sup>1</sup>H-<sup>1</sup>H TROESY (250 ms) NMR spectrum of compound 18



Figure 38S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 18



Figure 39S. <sup>1</sup>H-<sup>13</sup>C 1,1-ADEQUATE NMR spectrum of compound 18



Figure 40S. <sup>1</sup>H-<sup>13</sup>C HMBC (8 Hz) NMR spectrum of compound 18



Figure 41S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 19 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 42S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 21 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O





Figure 43S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 22 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 44S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 23 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 45S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 24 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 46S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 25 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



. Murata, T., Miyase, T., Yoshizaki, F., 2012. Hyaluronidase Inhibitors from Keiskea japonica. Chem. Pharm. Bull. (Tokyo). 60, 121–128. doi:10.1248/cpb.60.121 2. Chen, Y.-S., Yu, H.-M., Shie, J.-J., Cheng, T.-J.R., Wu, C.-Y., Fang, J.-M., Wong, C.-H., 2014. Chemical constituents of Plectranthus amboinicus and the synthetic analogs possessing anti-inflammatory activity. Bioorg. Med. Chem. 22, 1766–1772. doi:10.1016/j.bmc.2014.01.009





**Figure 48S.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 27 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH



Figure 49S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 28 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



1. Murata, T., Oyama, K., Fujiyama, M., Oobayashi, B., Umehara, K., Miyase, T., Yoshizaki, F., 2013. Diastereomers of lithospermic acid and lithospermic acid B from Monarda fistulosa and Lithospermum erythrorhizon Fitoterapia 91, 51–59. doi:10.1016/j.fitote.2013.08.009

Figure 50S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 29 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH



Figure 51S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 30 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 52S. <sup>1</sup>H NMR spectrum of compound 30



Figure 53S. <sup>13</sup>C DEPTQ NMR spectrum of compound 30



Figure 54S. 1H-1H COSY NMR spectrum of compound 30



Figure 55S. 1H-1H TROESY (250 ms) NMR spectrum of compound 30



Figure 56S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 30



Figure 57S. 1H-13C H2BC NMR spectrum of compound 30



Figure 58S. <sup>1</sup>H-<sup>13</sup>C HMBC (8 Hz) NMR spectrum of compound 30



1. O'Malley, S.J., Tan, K.L., Watzke, A., Bergman, R.G., Ellman, J.A., 2005. Total Synthesis of (+)-Lithospermic Acid by Asymmetric Intramolecular Alkylation via Catalytic C-H Bond Activation. J. Am. Chem. Soc. 127, 13496–13497. doi:10.1021/ja052680h 2. Murata, T., Oyama, K., Fujiyama, M., Oobayashi, B., Umehara, K., Miyase, T., Yoshizaki, F., 2013. Diastereomers of lithospermic acid and lithospermic acid B from Monarda fistulosa and Lithospermum erythrorhizon. Fitoterapia 91, 51–59. doi:10.1016/j.fitote.2013.08.009

Figure 59S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 31 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 60S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 32 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 61S. <sup>1</sup>H NMR spectrum of compound 32



Figure 62S. <sup>13</sup>C DEPTQ NMR spectrum of compound 32



Figure 63S. 1H-1H COSY NMR spectrum of compound 32



Figure 64S. <sup>1</sup>H-<sup>1</sup>H TROESY (250 ms) NMR spectrum of compound 32



Figure 65S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 32



Figure 66S. <sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 32







e Chem. Lett 4, 501–504. 8-94-017-9463-3

Zhang, H.J., Li, L.N., 1993. Salvianolic acid H, a new depside from Sarvia Cavascie Contract, and Cavascie C issa officinalis. Chem. Pharm. Bull. (Tokyo). 41, 1608–1611. doi:10.1248/cpb.41.1608 re Elucidation of Radical Scavengers from Thymus vulgaris Leaves. J. Nat. Prod. 65, 892–896. doi:10.1021/np010636j

Figure 68S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 33 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O







Figure 70S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 35 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH

'H NS16 CD30D 25° C - NS=16







Figure 72S. <sup>13</sup>C DEPTQ NMR spectrum of compound 35



Figure 73S. 1H-1H COSY NMR spectrum of compound 35



Figure 74S. <sup>1</sup>H-<sup>1</sup>H TROESY (250 ms) NMR spectrum of compound 35



Figure 75S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 35



Figure 76S. <sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 35







1. Tanaka, T., Nishimura, A., Kouno, I., Nonaka, G.I., Young, T.J., 1996. Isolation and characterization of yunnaneic acids A-D, four novel caffeic acid metabolites from Salvia yunnanensis. J. Nat. Prod. 59, 843–849. doi:10.1021/np960425s 2. Yan, X., 2015. Dan Shen (Salvia miltiorrhiza) in Medicine. Springer Netherlands, Dordrecht. doi:10.1007/978-94-017-9463-3

Figure 78S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 36 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH



1. OVENDEN, S., YU, J., SANWAN, S., SBERNA, G., MURRAYTAIT, R., RHODES, D., COX, S., COATES, J., WALSH, N., MEURERGRIMES, B., 2004. Globaidnan A: a lignan from Eucalyptus globoidea inhibits HIV integrase. Phytochemistry 65, 3255–3259. doi:10.1016/j.phytochem.2004.10.006 2. Fedoreyev, S.A., Veselova, M. V., Krivoschekova, O.E., Mischenko, N.P., Denisenko, V.A., Dmitrenok, P.S., Glazunov, V.P., Bulgakov, V.P., Tchernoded, G.K., Zhuravlev, Y.N., 2005. Caffeic Acid Metabolites from Entitichium sericeum Cell Cultures. Planta Med. 71, 446–451. doi:10.1055/s-2005.846141

Figure 79S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 37 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 80S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 38 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O



Figure 81S. <sup>1</sup>H NMR spectrum of compound 38



Figure 82S. <sup>13</sup>C DEPTQ NMR spectrum of compound 38



Figure 83S. <sup>1</sup>H-<sup>1</sup>H COSY NMR spectrum of compound 38



Figure 84S. <sup>1</sup>H-<sup>1</sup>H NOESY (300 ms) NMR spectrum of compound 38



Figure 85S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 38



Figure 86S. <sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 38







#### **Pulmitric acid B**

1. Murata, T., Watahiki, M., Tanaka, Y., Miyase, T., Yoshizaki, F., 2010. Hyaluronidase Inhibitors from Takuran, Lycopus lucidus. Chem. Pharm. Bull. (Tokyo). 58, 394–397. doi:10.1248/cpb.58.394

Figure 88S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 39 in CD<sub>3</sub>OD, 25°C







Figure 90S. <sup>13</sup>C DEPTQ NMR spectrum of compound 39



Figure 91S. 1H-1H COSY NMR spectrum of compound 39



Figure 92S. <sup>1</sup>H-<sup>1</sup>H NOESY (300 ms) NMR spectrum of compound 39



Figure 93S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 39



Figure 94S. <sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 39







1. Lee, H. J.; Cho, J.-Y.; Moon, J.-H. Chemical conversions of salvianolic acid B by decoction in aqueous solution. Fitoterapia 2012, 83, 1196–1204, doi:10.1016/j.fitote.2012.06.015.

**Figure 96S.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 40 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH



**Figure 97S.** <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 41 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O; ECD spectrum in MeOH



Figure 98S. <sup>1</sup>H NMR spectrum of compound 41



Figure 99S. <sup>13</sup>C DEPTQ NMR spectrum of compound 41



Figure 100S. <sup>1</sup>H-<sup>1</sup>H COSY NMR spectrum of compound 41



![](_page_55_Figure_1.jpeg)

<sup>1</sup>H-<sup>1</sup>H TROESY (250 ms) NMR spectrum of compound 41

![](_page_55_Figure_3.jpeg)

Figure 102S. <sup>1</sup>H-<sup>13</sup>C HSQC NMR spectrum of compound 41

![](_page_56_Figure_0.jpeg)

![](_page_56_Figure_1.jpeg)

<sup>1</sup>H-<sup>13</sup>C H2BC NMR spectrum of compound 41

![](_page_56_Figure_3.jpeg)

Figure 104S. <sup>1</sup>H-<sup>13</sup>C HMBC (8 Hz) NMR spectrum of compound 41

![](_page_57_Figure_0.jpeg)

![](_page_57_Figure_1.jpeg)

1. Murata, T., Watahiki, M., Tanaka, Y., Miyase, T., Yoshizaki, F., 2010. Hyaluronidase Inhibitors from Takuran, Lycopus lucidus. Chem. Pharm. Bull. (Tokyo). 58, 394–397. doi:10.1248/cpb.58.394

Figure 106S. <sup>1</sup>H (500 MHz) and <sup>13</sup>C (125 MHz) NMR data of compound 44 in CD<sub>3</sub>OD, 25°C; on-line PDA UV spectrum in MeCN/H<sub>2</sub>O

### Table S1.

No.	Compound name	Regression equation	R <sup>2</sup>	Calibration range	LOD	LOQ
				[µg/mL]	[µg/mL]	[µg/mL]
1	Danshensu	y=-0.0002x <sup>2</sup> +0.0194x+0.0045	0.9977	0.2-35	0.1	0.4
2	Menisdaurin	y=-0.0004x <sup>2</sup> +0.0374x+0.0067	0.9987	0.2-35	0.1	0.4
3	3-O-(E)-caffeoyl-L-threonic	$x = 0.0024x^{2} \pm 0.0577x \pm 0.0053$	0 9995	0 2 12	0.1	0.3
	acid	y==0.0024x +0.0377x+0.0033	0.9995	0.2-12	0.1	0.5
4	2-O-(E)-caffeoyl-L-threonic	$x = 0.0004 x^{2} + 0.0400 x + 0.0074$	0 9989	0.2-35	0.1	0.4
	acid	y=-0.0004x +0.0400x+0.0074	0.9909	0.2-55	0.1	0.4
5	Lycoperodine-1	y=-0.0006x <sup>2</sup> +0.0387x+0.0114	0.9971	0.2-35	0.1	0.4
6	Chlorogenic acid	y=-0.0109x <sup>2</sup> +0.2568x+0.0126	0.9998	0.2-12	0.1	0.3
7	Actinidioionoside	y=-0.0013x <sup>2</sup> +0.0762x+0.0342	0.9937	0.2-12	0.1	0.3
8	Caffeic acid	y=-0.0003x <sup>2</sup> +0.0447x+0.0229	0.9982	0.2-60	0.1	0.3
9	Cryptochlorogenic acid		Calibrated using co	ompound 6 curve.		
10	3'- $O$ -( $E$ )-Feruoyl- $\alpha$ -					
	sorbopyranosyl-(2' $\rightarrow$ 1)- $\alpha$ -	y=-0.004x <sup>2</sup> +0.0902x+0.0113	0.9988	0.2-12	0.1	0.4
	glucopyranoside					
11	2-O-(E)-caffeoyl-D-glyceric	$x = 0.0004x^{2} + 0.0477x + 0.021$	0.0070	0.2.60	0.2	0.6
	acid	y0.0004x-+0.0477x+0.021	0.9979	0.3-00	0.2	0.0
12	4-O-(E)-caffeoyl-L-threonic	$x = 0.005x^{2} + 0.1121x + 0.0107$	0.0007	0 2 12	0.1	0.2
	acid	y=-0.003x-+0.1131x+0.0107	0.9992	0.2-12	0.1	0.3
13	Neochlorogenic acid	y=-0.0109x <sup>2</sup> +0.2568x+0.0126	0.9998	0.2-12	0.1	0.3
14	3-O-(E)-caffeoyl-D-glyceric	$x = 0.0006x^{2} + 0.0717x + 0.0267$	0.0096	0.2.60	0.1	0.2
	acid	y=-0.0006x2+0.0717x+0.0267	0.9986	0.2-60	0.1	0.3
15	3-O-p-coumaroyl-quinic acid	y=-0.0015x <sup>2</sup> +0.0967x+0.0358	0.9959	0.2-35	0.1	0.4
16	4-O-p-coumaroyl-quinic acid	Calibrated using compound <b>15</b> curve.				
17	5-O-p-coumaroyl-quinic acid		Calibrated using co	mpound 15 curve.		
18	Globoidnan B	y=-0.0003x <sup>2</sup> +0.0489x+0.0157	0.9989	0.4-60	0.3	0.9
19	Rutin	y=-0.0012x <sup>2</sup> +0.0739x+0.0261	0.9948	0.2-35	0.1	0.3
20	Nicotiflorin isomer	Calibrated using compound 24	curve.			
21	Quercetin 3-O-β-glucoside	y=-0.0064x <sup>2</sup> +0.1414x+0.0189	0.9984	0.2-12	0.1	0.3
22	Yunnaneic acid E	$y=-0.0001x^2+0.0077x-0.001$	0.9984	0.5-60	0.4	1.2
23	Quercetin 3-O-(6"-O-malonyl)-		0.0044	0.0.05	0.1	0.0
	β-glucoside	y=-0.0004x <sup>2</sup> +0.0265x+0.009	0.9944	0.2-35	0.1	0.3
24	Nicotiflorin	y=-0.0018x <sup>2</sup> +0.1125x+0.0327	0.9966	0.2-35	0.1	0.4
25	Astragalin	y=-0.002x <sup>2</sup> +0.1069x+0.0483	0.9933	0.2-35	0.1	0.3
26	Shimobashiric acid C	$y=-0.0001x^2+0.0509x+0.0116$	0.9993	0.3-60	0.2	0.9
27	Rosmarinic acid	y=-0.0001x <sup>2</sup> +0.0509x+0.0116	0.9993	0.2-12	0.1	0.3
28	Kaempferol 3-O-(6"-O-		0.0079	0.2.25	0.1	0.2
	malonyl)-β-glucoside	$y = -0.0004x^2 + 0.0284x + 0.0073$	0.9968	0.2-35	0.1	0.3
29	Monardic acid A	y=-0.0001x <sup>2</sup> +0.0017x+0.0032	0.9858	0.5-60	0.5	1.5
30	Yunnaneic acid E-1		Not me	asured		
31	Lithospermic acid A	y=-0.0001x <sup>2</sup> +0.0095x+0.0059	0.9997	0.2-60	0.3	0.9
32	Pulmonarioside A	y=-0.0003x <sup>2</sup> +0.0331x+0.0145	0.9975	0.2-60	0.2	0.6
33	Salvianolic acid H	y=-0.0005x <sup>2</sup> +0.0683x+0.0135	0.9991	0.2-60	0.1	0.3
34	Lithospermic acid B		Not me	asured		
35	Pulmonarioside B	y=-0.0002x <sup>2</sup> +0.0291x+0.0105	0.9982	0.2-60	0.1	0.3
36	Yunnaneic acid B	y=-0.0001x <sup>2</sup> +0.0024x-0.0017	0.9988	0.2-60	0.1	0.3
37	Globoidnan A	y=-0.0072x <sup>2</sup> +0.1572x+0.0108	0.9995	0.2-12	0.1	0.3
38	Pulmitric acid A	y=-0.0128x <sup>2</sup> +0.2597x+0.0201	0.9994	0.2-12	0.1	0.3
39	Pulmitric acid B	y=-0.0026x <sup>2</sup> +0.2597x+0.0201	0.9954	0.2-35	0.1	0.3
40	Isosalvianolic acid A	y=-0.0117x <sup>2</sup> +0.2729x+0.0298	0.9986	0.2-12	0.1	0.3
41	Isosalvianolic acid A-1	Calibrated using compound <b>40</b> curve.				
42	Isosalvianolic acid A isomer	Calibrated using compound <b>40</b> curve.				
43	Rosmarinic acid methyl ester	y=-0.0154x <sup>2</sup> +0.3333x+0.0683	0.9973	0.2-12	0.1	0.3
44	Salvianolic acid H-9"-	$x = 0.001 x^{2+0.0601 x+0.0125}$	0.0004	0.2.25	0.1	0.2
	methylester	y0.001x-+0.0691x+0.0125	0.9984	0.2-35	0.1	0.3
45	Lycopic acid C	Not measured				

![](_page_59_Figure_0.jpeg)

Figure 107S. Frequency distribution of the relative standard deviation for the peak intensities and peak numbers in QC samples